Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Japan Eyes Different Supply Routes for Non-Pfizer COVID-19 Vaccines: Kono
The Japanese government believes that it is necessary to consider different supply routes for COVID-19 vaccines that might be newly granted approval, apart from the current channel for Pfizer’s shots, vaccination campaign minister Taro Kono said on April 23. Since…
To read the full story
Related Article
- Vaccines for All People to Be Delivered to Local Govts by October-End: Kono
June 30, 2021
- 1st Vaccine Doses to Be Delivered for Half of Elderly by May: Kono
April 5, 2021
- Govt Plans Switch to 6-Dose Syringes for Elderly “Sometime in May”: Kono
March 29, 2021
- COVID-19 Vaccines to Be Shipped with 6-Dose Syringes from Week of April 12, for Use in 2nd-in-Line HCPs
March 23, 2021
- All Municipalities to Get 2nd Doses for HCPs by Week of May 10: Minister
March 15, 2021
- Japan Speeds Up Vaccine Delivery for HCPs, Kono Says All 2nd Doses to Reach Municipalities in 1st Half of May
March 8, 2021
- Govt to Deliver 1st COVID-19 Vaccine Dose for 3.7 Million HCPs in April: Minister
March 1, 2021
- Japan to Start Elderly Vaccine Rollout from April 12: Minister
February 25, 2021
- Up to 1.17 Million Vaccine Doses to Be Shipped for HCPs in First Half of March
February 22, 2021
REGULATORY
- 10 Firms Win Approval for Bilanoa Generics, 2 Contenders for Fycompa
February 17, 2026
- MHLW to Brand OTC-Like Drug Cost Rule as “Partially Non-Insured Care”
February 17, 2026
- Taiyo Pharma’s Propranolol Designated as Drug for Specific Use
February 17, 2026
- Japan Grants Orphan Tag to Bayer, Incyte Drugs, and 12 Others
February 17, 2026
- Japan to Delist 387 Drugs from NHI Price List, Including Renivace
February 16, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…